Denosumab does not increase infection risk in rheumatic disease patients when used alone or in combination with biologic dmards

Patients with rheumatic diseases who are treated with denosumab (Prolia®, Xgeva®) either alone, or in combination with either biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs), do not appear to have a significant increased risk of infections.

Leave a Reply

Your email address will not be published. Required fields are marked *